JP2020500837A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020500837A5 JP2020500837A5 JP2019517034A JP2019517034A JP2020500837A5 JP 2020500837 A5 JP2020500837 A5 JP 2020500837A5 JP 2019517034 A JP2019517034 A JP 2019517034A JP 2019517034 A JP2019517034 A JP 2019517034A JP 2020500837 A5 JP2020500837 A5 JP 2020500837A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- assembled
- hcv
- order
- antigens
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims description 101
- 102000036639 antigens Human genes 0.000 claims description 101
- 108091007433 antigens Proteins 0.000 claims description 101
- 238000000034 method Methods 0.000 claims description 42
- 239000000203 mixture Substances 0.000 claims description 26
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 claims description 12
- 230000003472 neutralizing effect Effects 0.000 claims description 8
- 208000015181 infectious disease Diseases 0.000 claims description 7
- 235000018417 cysteine Nutrition 0.000 claims description 5
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 claims description 5
- 102000005962 receptors Human genes 0.000 claims description 5
- 108020003175 receptors Proteins 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 4
- 125000000539 amino acid group Chemical group 0.000 claims description 4
- 239000003638 chemical reducing agent Substances 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 238000012544 monitoring process Methods 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 108010003533 Viral Envelope Proteins Proteins 0.000 claims description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 3
- 208000006454 hepatitis Diseases 0.000 claims description 3
- 231100000283 hepatitis Toxicity 0.000 claims description 3
- 230000028993 immune response Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000035772 mutation Effects 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- -1 carrier Substances 0.000 claims description 2
- 239000007800 oxidant agent Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 239000000758 substrate Substances 0.000 claims description 2
- 229960005486 vaccine Drugs 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 102000008482 12E7 Antigen Human genes 0.000 description 2
- 108010020567 12E7 Antigen Proteins 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2016903961A AU2016903961A0 (en) | 2016-09-29 | Refolded glycoproteins for vaccine production | |
| AU2016903961 | 2016-09-29 | ||
| PCT/AU2017/051037 WO2018058177A1 (en) | 2016-09-29 | 2017-09-22 | Assembled glycoproteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020500837A JP2020500837A (ja) | 2020-01-16 |
| JP2020500837A5 true JP2020500837A5 (enExample) | 2021-04-30 |
| JP7068284B2 JP7068284B2 (ja) | 2022-05-16 |
Family
ID=61762303
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019517034A Active JP7068284B2 (ja) | 2016-09-29 | 2017-09-22 | アセンブルした糖タンパク質 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12162906B2 (enExample) |
| EP (1) | EP3519424A4 (enExample) |
| JP (1) | JP7068284B2 (enExample) |
| KR (2) | KR20240122578A (enExample) |
| CN (1) | CN110049993A (enExample) |
| AU (1) | AU2017334263B2 (enExample) |
| IL (1) | IL265524B2 (enExample) |
| WO (1) | WO2018058177A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4149541A4 (en) * | 2020-05-11 | 2024-06-05 | Macfarlane Burnet Institute for Medical Research and Public Health Limited | NUCLEIC ACID-BASED HEPATITIS C VACCINE COMPRISING A VARIABLE-DOMAIN-DELETED E2 POLYPEPTIDE |
| CN112285361B (zh) * | 2020-09-27 | 2023-12-05 | 中国人民解放军空军军医大学 | 排除抗-cd38单克隆抗体药物对抗人球蛋白检测干扰的试剂 |
| CN115389681B (zh) * | 2022-11-01 | 2023-01-20 | 常州百瑞吉生物医药有限公司 | 一种巯基化透明质酸衍生物中二硫苏糖醇残留的检测方法 |
| WO2025231336A1 (en) * | 2024-05-02 | 2025-11-06 | Avista Therapeutics, Inc. | Adeno-associated virus vectors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG71728A1 (en) * | 1994-07-29 | 2000-04-18 | Innogenetics Nv | Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use |
| EP1463521A4 (en) | 2001-12-17 | 2009-06-24 | Us Gov Health & Human Serv | INHIBITOR OF GP41 |
| WO2003051912A2 (en) * | 2001-12-18 | 2003-06-26 | Innogenetics N.V. | Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use |
| WO2008022401A1 (en) | 2006-08-25 | 2008-02-28 | The Macfarlane Burnet Institute For Medical Research And Public Health Limited | Recombinant hcv e2 glycoprotein |
| EP2600894B1 (en) * | 2010-08-04 | 2017-02-01 | The Macfarlane Burnet Institute For Medical Research And Public Health Ltd | Modified hepatitis c virus proteins |
| CA2856565A1 (en) | 2010-11-26 | 2012-05-31 | The Macfarlane Burnet Institute For Medical Research And Public Health Ltd. | Multimeric hepatitis virus (hcv) envelope 2 (e2) glycoprotein |
-
2017
- 2017-09-22 WO PCT/AU2017/051037 patent/WO2018058177A1/en not_active Ceased
- 2017-09-22 US US16/337,900 patent/US12162906B2/en active Active
- 2017-09-22 JP JP2019517034A patent/JP7068284B2/ja active Active
- 2017-09-22 KR KR1020247025714A patent/KR20240122578A/ko active Pending
- 2017-09-22 AU AU2017334263A patent/AU2017334263B2/en active Active
- 2017-09-22 CN CN201780063166.XA patent/CN110049993A/zh active Pending
- 2017-09-22 EP EP17854239.5A patent/EP3519424A4/en active Pending
- 2017-09-22 KR KR1020197011934A patent/KR20190078574A/ko active Pending
-
2019
- 2019-03-20 IL IL265524A patent/IL265524B2/en unknown
-
2024
- 2024-12-09 US US18/974,404 patent/US20250215048A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yong et al. | Recent advances in the vaccine development against Middle East respiratory syndrome-coronavirus | |
| AU2012269907B2 (en) | Vaccine composition comprising an inactivated chikungunya virus strain | |
| CN104428312A (zh) | 用于登革病毒表位的方法和组合物 | |
| US20230018080A1 (en) | Methods and compositions for recombinant dengue viruses or vaccine and diagnostic development | |
| Buczkowski et al. | Morbillivirus vaccines: recent successes and future hopes | |
| JP2012503011A5 (ja) | 慢性ｃ型肝炎ウイルス感染症のための酵母系免疫治療組成物 | |
| Merino-Ramos et al. | Protection of a single dose west nile virus recombinant subviral particle vaccine against lineage 1 or 2 strains and analysis of the cross-reactivity with Usutu virus | |
| US10870682B2 (en) | Methods and compositions for dengue virus vaccines | |
| JP2020500837A5 (enExample) | ||
| US10398768B2 (en) | Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development | |
| HK1206366A1 (en) | Vaccines and methods for creating a vaccine for inducing immunity to all dengue virus serotypes | |
| Fan et al. | Genotype I of Japanese encephalitis virus virus-like particles elicit sterilizing immunity against genotype I and III viral challenge in swine | |
| JP7545955B2 (ja) | インフルエンザｈａスプリットワクチンの製造方法 | |
| Zhu et al. | An engineered Japanese encephalitis virus mRNA-lipid nanoparticle immunization induces protective immunity in mice | |
| JP2020536107A5 (enExample) | ||
| Ter Meulen | Lassa fever: implications of T-cell immunity for vaccine development | |
| Gattinger et al. | Fusion protein-based COVID-19 vaccines exemplified by a chimeric vaccine based on a single fusion protein (W-PreS-O) | |
| Camus | Development and characterization of Lassa virus vaccines and mouse model | |
| Willis | The Effect of Maternal Antibodies on Anti-viral Immunity in Infant Mice | |
| Deng et al. | Characterization of a novel neutralizing monoclonal antibody that recognizes the fusion loop of Flavivirus envelope protein | |
| Caine | Understanding host adaptation and disease progression of enterovirus 71 using mouse models, reverse genetics, and in vivo imaging | |
| WO2015133467A1 (ja) | Ｃ型肝炎ウイルスのワクチン及び診断に用いるためのＨＢｃ／ＨＣＶ Ｅ２ペプチドキメラタンパク質 |